May 19, 2023 – Thermo Fisher Scientific has opened a new sterile drug facility in Singapore that will better enable customers to deliver new medicines and vaccines in the Asia-Pacific market.
The new facility also marks a significant milestone and investment in pandemic preparedness for Singapore, which is fast emerging as a biomedical hub in the Asia-Pacific region.
The current Good Manufacturing Practices (cGMP) facility will provide rapid vaccine fill-finish capabilities along with Thermo Fisher’s end-to-end pharmaceutical development and manufacturing services.
The new facility includes a high-speed, fully automated aseptic fill-finish line for small and large molecules. This strategic investment in Singapore complements new research capabilities at Thermo Fisher Scientific’s Customer Experience Center and Bioprocess Design Center, two other operational lab facilities that showcase the latest bioprocessing, life science, and analytical technologies.
With more than 250 products across diverse fields including molecular biology, genetic analysis and sequencing, chromatography and mass spectrometry, and cell therapy, the Customer Experience Center features an extensive product portfolio for Asia. Additionally, the Bioprocess Design Center provides expertise in bioprocessing and process scale-up to support scientists and engineers with education and customized services to accelerate process development.
Together, these sites allow Thermo Fisher to better enable customers to accelerate their research, as well as develop and commercialize new medicines and vaccines in the Asia-Pacific market.